Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Non Operating Income (2018 - 2025)

Historic Non Operating Income for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to -$1.1 million.

  • Precision Biosciences' Non Operating Income fell 12278.35% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 7868.81%. This contributed to the annual value of $33.3 million for FY2024, which is 265674.11% up from last year.
  • Precision Biosciences' Non Operating Income amounted to -$1.1 million in Q3 2025, which was down 12278.35% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Precision Biosciences' Non Operating Income registered a high of $12.8 million during Q1 2024, and its lowest value of -$7.3 million during Q4 2022.
  • Moreover, its 5-year median value for Non Operating Income was $96000.0 (2023), whereas its average is $1.7 million.
  • As far as peak fluctuations go, Precision Biosciences' Non Operating Income surged by 3113703.7% in 2021, and later tumbled by 627083.33% in 2022.
  • Over the past 5 years, Precision Biosciences' Non Operating Income (Quarter) stood at $8.4 million in 2021, then plummeted by 186.77% to -$7.3 million in 2022, then soared by 119.9% to $1.5 million in 2023, then surged by 387.71% to $7.1 million in 2024, then plummeted by 115.56% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, -$1.6 million for Q2 2025, and $1.5 million during Q1 2025.